Pharmaceutical giant AbbVie exceeded Q4 expectations, reporting adjusted earnings per share of $2.71, above the $2.65 estimate. Revenue also beat forecasts, reaching $16.62 billion against a $16.39 billion consensus. However, shares dipped by 2.5% in premarket trading. This mixed reaction suggests investors are weighing strong performance against other factors.

Immunology and neuroscience drove AbbVie's growth. The immunology portfolio, including Skyrizi and Rinvoq, saw substantial revenue increases. While Humira sales declined due to biosimilar competition, the overall portfolio offset these losses. The company's forecast for 2026 adjusted earnings per share is also positive, at $14.37-$14.57 per share.

The decline in Humira sales has been a key focus for AbbVie as biosimilars gain market share. The company is successfully navigating this transition, as evident by the overall revenue growth. Investors will be watching the continued performance of Skyrizi and Rinvoq, along with the neuroscience portfolio, to sustain future growth.

Strong performance in key product areas, particularly in immunology, is helping AbbVie maintain its position in a competitive market. Investors are likely assessing the long-term implications of these results, including the company's ability to diversify revenue streams. The next step is to see if AbbVie can sustain this momentum.